Hepatic Encephalopathy

1. Clinical Overview

Summary

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities occurring in patients with liver dysfunction and/or portosystemic shunting, characterized by reversible impairment of consciousness and cognitive function. [1] The condition arises from the accumulation of gut-derived neurotoxins, predominantly ammonia, due to impaired hepatic clearance and portosystemic shunting that bypasses normal hepatic metabolism. [2] HE ranges from subtle subclinical cognitive deficits (minimal or covert HE) to profound coma (grade IV), with manifestations including altered mental status, personality changes, sleep-wake cycle disturbances, and motor abnormalities such as asterixis. [3]

The clinical course is typically episodic, often precipitated by identifiable triggers including infection (particularly spontaneous bacterial peritonitis), gastrointestinal bleeding, constipation, electrolyte disturbances, renal impairment, or sedative medications. [4] The West Haven Criteria provide standardized grading from minimal HE through grades I-IV based on cognitive, behavioral, and consciousness alterations. [5] Management centers on identifying and treating precipitants, reducing ammonia production and absorption with lactulose, and secondary prevention with rifaximin in recurrent cases. [6,7] The development of overt HE carries prognostic significance, with 1-year mortality rates of 40-50% following first episode and indicating the need for liver transplantation evaluation. [8]

Key Facts

• Definition: Neuropsychiatric syndrome in patients with liver dysfunction due to accumulation of neurotoxins that are inadequately cleared by the liver [1]
• Classification: Type A (acute liver failure), Type B (portosystemic bypass without intrinsic hepatocellular disease), Type C (cirrhosis with portal hypertension/portosystemic shunts) [9]
• Prevalence: 30-45% of cirrhotic patients develop overt HE during disease course; minimal HE present in 30-80% depending on detection methods [10,11]
• Mortality: 1-year survival after first episode of overt HE is 42%; median survival 12 months [8]
• Grading: West Haven Criteria grades 0 (minimal) through IV (coma) based on consciousness, behavior, and neurological findings [5]
• Pathognomonic Feature: Asterixis (flapping tremor) in appropriate clinical context, though absent in deep encephalopathy [12]
• First-line Treatment: Lactulose 30-45 mL TID titrated to 2-3 soft stools daily plus identification and treatment of precipitant [6]
• Secondary Prevention: Rifaximin 550 mg BD added to lactulose reduces recurrence by 58% [7]

Clinical Pearls

Precipitant Pearl: Up to 90% of HE episodes have an identifiable precipitant. Systematic search for infection (especially SBP), GI bleeding, constipation, electrolyte disturbances (hypokalemia, hyponatremia), renal failure, sedatives, and TIPS procedure is mandatory. [4]

Lactulose Pearl: Lactulose works through dual mechanisms - acidification of colonic contents (trapping ammonia as non-absorbable NH4+) and osmotic laxative effect reducing transit time and ammonia-producing bacteria. Target 2-3 soft stools daily; over-treatment causes dehydration and electrolyte disturbance. [13]

Ammonia Pearl: Serum ammonia correlates poorly with HE severity and should not be used to diagnose, grade, or monitor HE. Normal ammonia does not exclude HE; elevated ammonia alone does not confirm HE. Venous samples adequate; arterial sampling not required. [14,15]

Protein Pearl: Historical protein restriction is obsolete and harmful. Maintain 1.2-1.5 g/kg/day protein to prevent sarcopenia and malnutrition, which worsen outcomes. Vegetable-based proteins may be better tolerated than animal proteins. [16]

---

2. Epidemiology

Incidence and Prevalence

Hepatic encephalopathy represents a major complication of both acute and chronic liver disease with significant epidemiological burden. The prevalence varies substantially based on HE type, underlying liver disease etiology, and detection methods employed. [10]

Cirrhosis-related HE (Type C):

• Minimal (covert) HE: 30-84% of cirrhotic patients depending on diagnostic tests used (psychometric testing vs. critical flicker frequency vs. Stroop test) [11,17]
• Overt HE: 30-45% of cirrhotic patients experience at least one episode during disease course [10]
• Annual incidence of first episode: approximately 5-25% per year depending on cirrhosis severity [18]
• Recurrence rate: 40% within 6 months after first episode without maintenance therapy; reduced to 20% with rifaximin plus lactulose [7]

Acute Liver Failure (Type A):

• HE develops in virtually 100% of patients with acute liver failure by definition [19]
• Grade III-IV encephalopathy occurs in 60-80% of ALF cases [20]
• Associated with intracranial hypertension in 25-80% of grade IV encephalopathy cases [19]

TIPS-related HE (post-TIPS shunt):

• New or worsening HE develops in 10-50% within first year after TIPS placement [21]
• Persistent HE requiring treatment: 5-35% depending on shunt diameter and patient selection [22]
• Risk higher with smaller covered stent grafts versus bare metal stents

Risk Factors for Development

Patient factors:

• Advanced cirrhosis (Child-Pugh B/C, MELD > 15) [23]
• Prior episodes of HE (strongest predictor of recurrence) [24]
• Hyponatremia (less than 130 mmol/L) - independent predictor [25]
• Sarcopenia and malnutrition [26]
• Age > 65 years [27]
• Hypoalbuminemia [28]

Precipitating factors (present in 80-90% of episodes) [4]:

• Infection: 25-35% of episodes (SBP, UTI, pneumonia, bacteremia)
• GI bleeding: 15-25% (increases protein load)
• Constipation: 10-15%
• Electrolyte disturbances: 10-20% (hypokalemia, hyponatremia)
• Renal impairment: 10-15%
• Sedative/psychoactive medications: 5-10%
• Dehydration from diuretics: 10-15%
• TIPS creation or revision: variable
• Dietary protein overload: less than 5% (less common than historically believed)

Socioeconomic Impact

Hepatic encephalopathy imposes substantial healthcare and societal burden:

• Hospital admissions: HE accounts for 0.33% of all US hospital admissions and 1.2% of GI-related admissions [29]
• Healthcare costs: Estimated $7.2 billion annually in US for HE-related hospitalizations [30]
• Median length of stay: 5-7 days per HE admission [29]
• Readmission rates: 30-day readmission rate of 30-40% [31]
• Quality of life: Marked reduction in health-related QoL, impaired ability to work, social isolation even with minimal HE [32]
• Driving safety: Minimal HE associated with driving impairment equivalent to blood alcohol 0.05-0.08% [33]
• Caregiver burden: Significant impact on family members/caregivers with increased stress and reduced productivity [34]

---

3. Pathophysiology

Ammonia Metabolism and Neurotoxicity

Ammonia represents the most extensively studied neurotoxin in HE pathogenesis, though the syndrome is multifactorial involving multiple gut-derived toxins, neuroinflammation, and neurotransmitter alterations. [2,35]

Normal Ammonia Metabolism: In health, ammonia (NH3) is produced primarily in the colon from bacterial metabolism of proteins, amino acids, and urea, and in the small intestine from glutamine metabolism. [36] The portal circulation delivers ammonia to the liver where hepatocytes convert it to urea via the urea cycle (periportal hepatocytes) and to glutamine via glutamine synthetase (perivenous hepatocytes). [37] Normal arterial ammonia concentration is 11-35 μmol/L; portal venous levels are 2-3 times higher but are effectively cleared by first-pass hepatic extraction (80-90%). [38]

HE-Associated Ammonia Dysregulation: In cirrhosis and portal hypertension, two mechanisms lead to systemic hyperammonemia: [2]

1. Impaired hepatocellular function: Reduced functional hepatocyte mass and decreased urea cycle enzyme activity impair ammonia detoxification
2. Portosystemic shunting: Portal-systemic collaterals (spontaneous or surgical/TIPS) bypass hepatic clearance, allowing direct entry of ammonia into systemic circulation

Skeletal muscle becomes an important alternative site of ammonia detoxification through glutamine synthesis, explaining why sarcopenia is a risk factor for HE. [26] Renal ammonia production from glutamine increases in hyperammonemia but cannot compensate adequately. [39]

Cerebral Ammonia Toxicity: Ammonia crosses the blood-brain barrier as lipophilic NH3 (not ionized NH4+). [40] Within the brain, astrocytes are the primary cells affected as they contain glutamine synthetase and convert ammonia to glutamine. [41] The pathophysiological cascade includes:

1. Astrocyte swelling (Alzheimer type II astrocytosis): Glutamine accumulation creates osmotic stress, causing astrocyte swelling and cytotoxic edema. [42] This is particularly relevant in acute liver failure where cerebral edema and intracranial hypertension occur.

2. Oxidative and nitrosative stress: Ammonia induces mitochondrial dysfunction in astrocytes, generating reactive oxygen species (ROS) and reactive nitrogen species (RNS), leading to oxidative damage. [43]

3. Energy metabolism impairment: Ammonia depletes α-ketoglutarate (consumed in glutamine synthesis), impairing the tricarboxylic acid cycle and ATP generation. [44]

4. Blood-brain barrier dysfunction: Astrocyte swelling and oxidative stress compromise BBB integrity, allowing further toxin entry. [45]

Neurotransmitter Alterations

GABAergic Tone Enhancement: Increased GABAergic neurotransmission contributes to HE neurological manifestations. [46] Mechanisms include:

• Increased brain GABA synthesis from ammonia
• Upregulation of peripheral benzodiazepine receptors on astrocytes
• Increased neurosteroids with GABA-agonist activity
• Enhanced sensitivity of GABA-A receptors

This GABAergic hypothesis explains the occasional benefit of flumazenil (GABA-antagonist) in selected HE patients. [47]

Glutamatergic System: Paradoxically, despite glutamine accumulation, glutamate neurotransmission is impaired. Ammonia downregulates glutamate receptors (NMDA, AMPA) on neurons, reducing excitatory neurotransmission. [48] This contributes to cognitive slowing and reduced consciousness.

Monoaminergic Imbalance: Altered ratio of aromatic amino acids (phenylalanine, tyrosine, tryptophan) to branched-chain amino acids (leucine, isoleucine, valine) leads to increased brain synthesis of false neurotransmitters (octopamine, phenylethylamine) and increased serotonin. [49] This contributes to altered consciousness and sleep-wake disturbances.

Inflammation and Neuroinflammation

Systemic Inflammation: Cirrhosis is characterized by systemic inflammation with elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18). [50] Gut barrier dysfunction and bacterial translocation drive ongoing immune activation. Infections precipitate HE partly through cytokine-mediated effects on brain function. [51]

Neuroinflammation: Activated microglia and reactive astrocytes release pro-inflammatory mediators in the brain. [52] Peripheral inflammatory signals cross the BBB and activate central inflammatory pathways. Neuroinflammation synergizes with ammonia toxicity, creating a vicious cycle. [53]

Additional Contributing Factors

Manganese Deposition: Chronic liver disease leads to manganese accumulation in basal ganglia (globus pallidus), visible as T1 hyperintensity on MRI. [54] Manganese contributes to parkinsonian features occasionally seen in cirrhotic patients and may worsen cognitive function.

Mercaptans and Other Toxins: Short-chain fatty acids, mercaptans (methanethiol), and phenols derived from gut bacterial metabolism contribute to HE. [55] Fetor hepaticus (sweet, musty breath) results from mercaptans. These toxins act synergistically with ammonia.

Zinc Deficiency: Zinc is a cofactor for urea cycle enzymes. Cirrhotic patients are commonly zinc-deficient, potentially impairing ammonia metabolism. [56] Zinc supplementation shows modest benefit in some studies.

---

4. Clinical Presentation

West Haven Grading Criteria

The West Haven Criteria (WHC) provide standardized clinical grading based on consciousness level, intellectual function, and neurological findings. [5] This remains the most widely used classification despite interobserver variability.

Clinical Application:

• Minimal HE: Requires specialized testing (PHES battery, Stroop test, critical flicker frequency) as routine examination is normal. Prevalence 30-80% but often unrecognized. [11]
• Grades I-II: Most common presentations; patients ambulatory but need supervision
• Grades III-IV: Medical emergency requiring ICU admission, airway protection, and investigation for cerebral edema (especially in acute liver failure)

Classic Clinical Signs

Asterixis (Flapping Tremor): Pathognomonic sign when present in appropriate context, appearing at grade II and higher. [12] Technique: Patient extends arms and dorsiflexes wrists (or feet if obtunded); irregular, non-rhythmic lapses in sustained posture produce "flapping" motion. Results from intermittent loss of extensor tone. Bilateral but may be asymmetric. Absent in deep encephalopathy (grade IV) due to reduced consciousness. Non-specific - also seen in uremia, respiratory failure, other metabolic encephalopathies.

Fetor Hepaticus: Sweet, musty, fecal odor on breath resulting from mercaptans (methyl mercaptan) excreted via lungs. [57] Suggests significant portosystemic shunting. Present in ~10-15% of HE patients, more common in acute liver failure than cirrhotic HE.

Constructional Apraxia: Impaired ability to draw or construct simple figures (e.g., five-pointed star, interlocking pentagons, clock face). [58] Simple bedside test: serial copying of line-drawing tests or Number Connection Test-A. Sensitive for minimal and grade I HE.

Sleep-Wake Cycle Disturbance: Reversed sleep pattern (daytime somnolence, nighttime insomnia) often precedes overt confusion. [59] Results from altered melatonin metabolism and circadian rhythm disruption. Family members may report personality change before cognitive decline is apparent.

Motor Signs:

• Early: Fine tremor, bradykinesia, hypomimia (parkinsonian features from manganese and basal ganglia dysfunction) [54]
• Advanced: Hyperreflexia, extensor plantar responses (Babinski), muscle rigidity
• Rare: Seizures (less than 5%), transient focal deficits mimicking stroke

Spectrum of HE

Minimal (Covert) Hepatic Encephalopathy:

• Definition: Cognitive impairment not detectable on standard clinical examination but evident on specialized testing [11]
• Prevalence: 30-84% of cirrhotic patients [17]
• Manifestations: Impaired attention, working memory, psychomotor speed, visuospatial ability
• Functional impact: Impaired quality of life, reduced employability, unsafe driving [33], increased fall risk
• Detection: Psychometric Hepatic Encephalopathy Score (PHES), EncephalApp Stroop test, Critical Flicker Frequency
• Prognostic significance: Predicts development of overt HE and mortality [60]

Overt Hepatic Encephalopathy:

• Episodic: Precipitant-triggered, resolves with treatment (most common pattern)
• Recurrent: ≥2 episodes within 6 months despite treatment
• Persistent: Continuous cognitive impairment despite treatment (suggests need for transplantation)

Acute vs. Chronic HE:

• Type A (acute liver failure): Rapid progression (hours to days), high risk of cerebral edema and intracranial hypertension, high mortality without transplant
• Type C (cirrhosis): Episodic, slower evolution (days), cerebral edema rare, fluctuating course

Atypical Presentations

Hepatic Myelopathy: Rare complication (1-2%) of portosystemic shunting presenting with progressive spastic paraparesis, hyperreflexia, extensor plantar responses, sensory loss, and sphincter dysfunction mimicking spinal cord disease. [61] MRI may show cord signal changes. Irreversible; portosystemic shunt occlusion may stabilize.

Acquired Hepatocerebral Degeneration: Chronic, irreversible neurological syndrome in patients with long-standing portosystemic shunting, featuring cerebellar ataxia, choreoathetosis, dementia, dysarthria, and parkinsonian features. [62] Brain MRI shows basal ganglia T1 hyperintensity (manganese). Distinct from reversible episodic HE.

---

5. Differential Diagnosis

HE is a diagnosis of exclusion requiring systematic evaluation to rule out alternative or concurrent causes of altered mental status in liver disease patients. [63]

Structural Neurological Conditions

Intracranial Hemorrhage:

• Relevance: Cirrhotic patients have coagulopathy (prolonged INR), thrombocytopenia, and fall risk (minimal HE, alcohol use), predisposing to subdural hematoma, intracerebral hemorrhage, and subarachnoid hemorrhage
• Differentiation: Focal neurological deficits, severe headache, asymmetric pupils, evidence of trauma. CT head mandatory in grade III-IV HE or when focal signs present
• Key point: Coagulopathy does not reliably prevent bleeding; INR poorly predicts bleeding risk in cirrhosis due to balanced deficiency of pro- and anti-coagulant factors

Ischemic Stroke:

• Relevance: Cirrhotic patients have multiple vascular risk factors; acute thrombosis possible despite coagulopathy
• Differentiation: Sudden onset, focal deficits corresponding to vascular territory, CT/MRI findings
• Key point: HE can produce transient focal deficits rarely, but these are typically brief and fluctuating

Metabolic and Toxic Encephalopathies

Wernicke Encephalopathy:

• Relevance: Common in alcoholic liver disease; thiamine deficiency from malnutrition, alcohol, recurrent vomiting
• Classic triad (present in less than 10%): Confusion, ophthalmoplegia (horizontal nystagmus, lateral rectus palsy), ataxia [64]
• Differentiation: Eye movement abnormalities, ataxia disproportionate to encephalopathy, MRI showing symmetric T2 hyperintensity in mammillary bodies, thalamus, periaqueductal gray
• Management: Parenteral thiamine 500 mg TDS for 3-5 days before glucose administration to prevent Korsakoff syndrome

Uremic Encephalopathy:

• Relevance: Hepatorenal syndrome type 1 common in advanced cirrhosis; difficult to distinguish from HE
• Features: Nausea, asterixis, myoclonus, seizures (more common than HE), uremic frost, pericarditis
• Differentiation: Elevated urea disproportionate to creatinine, metabolic acidosis, uremic pericardial rub
• Key point: Both conditions often coexist; treatment of HE (lactulose) may worsen renal function through dehydration

Hyponatremia:

• Relevance: Present in 30-50% of hospitalized cirrhotic patients; acute drops (less than 125 mmol/L) cause encephalopathy [25]
• Differentiation: Serum sodium less than 125 mmol/L with rapid decline, seizures possible with severe hyponatremia (less than 115)
• Management: Cautious correction (6-8 mmol/L/24h maximum to avoid osmotic demyelination syndrome)

Hypoglycemia:

• Relevance: Impaired hepatic gluconeogenesis and glycogen stores, sepsis, alcohol, insulinoma
• Differentiation: Glucose less than 3.0 mmol/L, autonomic symptoms (sweating, tremor, palpitations), rapid response to glucose
• Key point: Always check fingerstick glucose in altered mental status

Infectious Causes

Meningitis/Encephalitis:

• Relevance: Cirrhotic patients are immunocompromised; ascites provides potential source for bacteremia
• Differentiation: Fever, neck stiffness, photophobia, severe headache, seizures
• Investigations: LP (if not contraindicated by coagulopathy/thrombocytopenia) showing pleocytosis, elevated protein, low glucose (bacterial), lymphocytosis (viral/TB), positive cultures/PCR
• Key point: Perform CT head before LP if focal signs, papilledema, or reduced consciousness (risk of herniation)

Septic Encephalopathy:

• Relevance: Infection is the most common HE precipitant (25-35%); sepsis itself causes encephalopathy independent of ammonia [51]
• Differentiation: Source of infection evident (SBP, pneumonia, UTI, skin/soft tissue), fever, hypotension, elevated lactate, SIRS criteria
• Key point: Sepsis precipitates HE through multiple mechanisms (inflammatory cytokines, protein load from tissue catabolism, renal impairment reducing ammonia excretion)

Toxic Causes

Alcohol Intoxication/Withdrawal:

• Acute intoxication: Serum ethanol level, breath odor, ataxia, dysarthria
• Withdrawal: Tremor, hallucinations (visual/tactile), seizures, autonomic hyperactivity (tachycardia, hypertension, diaphoresis), delirium tremens
• Key point: Benzodiazepines for withdrawal may worsen HE; use cautiously with close monitoring

Medication-Related:

• Sedatives/opioids: Check medication history; benzodiazepines, opiates, antipsychotics all precipitate or worsen HE
• Toxicity: Salicylates, lithium, anticholinergics may cause encephalopathy
• Flumazenil trial: May transiently reverse HE if GABAergic mechanisms predominant [47]

Systemic Conditions

Delirium from Any Cause:

• Relevance: Hospitalized cirrhotic patients have multiple risk factors (older age, malnutrition, polypharmacy, infection, metabolic derangement)
• Differentiation: Fluctuating course, inattention, disorganized thinking, acute onset triggered by hospitalization/surgery
• Key point: HE is a form of delirium; systematic search for precipitants overlaps substantially

Subdural Hygroma/Chronic Subdural Hematoma:

• Relevance: Insidious presentation over weeks; history of minor trauma often absent
• Differentiation: Gradual decline rather than episodic, headache, subtle focal signs
• Investigations: CT/MRI head showing extra-axial collection

Investigations to Exclude Differentials

Systematic workup when HE suspected:

• Bedside glucose: Exclude hypoglycemia immediately
• Neuroimaging (CT head): Grade III-IV encephalopathy, focal neurological signs, head trauma, new-onset seizures
• Lumbar puncture: Fever + encephalopathy without clear source; exclude meningitis/encephalitis
• EEG: Atypical features, seizure concern, distinguishing HE from structural/other metabolic causes
• Serum ammonia: Supportive but not diagnostic; do not rely on for diagnosis or monitoring [14]
• Comprehensive metabolic panel: Sodium, renal function, glucose, calcium, magnesium
• Septic screen: Blood cultures (×2), urine culture, CXR, diagnostic paracentesis (if ascites present)

---

6. Investigations

Diagnostic Approach

Hepatic encephalopathy is primarily a clinical diagnosis made in the context of liver disease and altered mental status after exclusion of alternative causes. [63] No single laboratory or imaging finding confirms HE; investigations serve to exclude differentials, identify precipitants, and assess severity of liver disease.

Ammonia Measurement

Limitations and Interpretation: Serum ammonia is the most overused and misinterpreted test in HE evaluation. [14,15]

• Diagnostic value: Sensitivity 47-85%, specificity 31-76% for HE diagnosis; poor correlation with HE grade [65]
• False negatives: Up to 10% of patients with clear clinical HE have normal ammonia levels
• False positives: Elevated ammonia occurs in absence of HE due to: GI bleeding, high-protein meals, muscle activity, hemolysis during sampling, prolonged tourniquet time, delayed sample processing
• Serial monitoring: Ammonia trends do not reliably track clinical improvement; not recommended for monitoring treatment response [14]

When to Measure:

• First episode of suspected HE: Elevated level supports diagnosis but normal level does not exclude it
• Markedly elevated level (> 200 μmol/L) in patient without liver disease: Consider urea cycle defects, organic acidemias (rare in adults)
• Not indicated: Routine monitoring during treatment, grading severity, predicting outcomes

Sampling Technique:

• Venous sample adequate; arterial sampling not necessary
• Minimize tourniquet time, process within 15 minutes on ice, avoid hemolysis
• Fasting sample preferred but not mandatory

Electroencephalography (EEG)

EEG Findings in HE: Progressive slowing of background rhythm correlates with HE severity. [66]

• Normal/minimal HE: Normal or minimal slowing
• Grade I: Theta range slowing (4-7 Hz)
• Grade II-III: Triphasic waves (TWs) - bilateral, symmetric, high-amplitude sharp waves with anterior-posterior lag, most prominent in frontocentral regions; generalized slowing [67]
• Grade IV: Delta range activity (1-3 Hz), very low amplitude, loss of reactivity

Triphasic Waves:

• Classically associated with HE but non-specific - also seen in uremia, hyponatremia, hyperthyroidism, medication toxicity (lithium, valproate), anoxic brain injury [67]
• Present in ~30% of HE patients; absence does not exclude diagnosis
• Morphology: Surface-positive sharp wave followed by negative and second positive component

Clinical Utility:

• Grade III-IV encephalopathy: Differentiate metabolic (HE) from structural causes
• Atypical features: Rule out non-convulsive seizures
• Prognosis in ALF: Absence of EEG reactivity predicts poor outcome
• Not routinely indicated in typical episodic HE with clear precipitant

Neuroimaging

CT Head: Indications:

• Grade III-IV encephalopathy (exclude structural lesions, assess for cerebral edema in ALF)
• Focal neurological deficits
• Suspicion of intracranial hemorrhage or stroke
• Head trauma
• New-onset seizures

Typical findings: Normal or cerebral atrophy Acute liver failure: May show loss of gray-white differentiation, sulcal effacement, cerebral edema

MRI Brain: T1-weighted imaging: Symmetric hyperintensity in globus pallidus, substantia nigra (manganese deposition) in chronic liver disease/portosystemic shunting [54]

• Correlates with chronic HE but does not correlate with acute episodes
• Does not require gadolinium

T2/FLAIR: Cerebral edema in acute liver failure (rare in cirrhotic HE) DWI: Cytotoxic edema pattern in ALF

Clinical utility: Exclude structural pathology; manganese deposition supports diagnosis of chronic portosystemic shunting but not acutely useful

Psychometric and Neurophysiological Testing

Indications: Detection of minimal (covert) HE when clinical examination normal [11]

Psychometric Hepatic Encephalopathy Score (PHES):

• Gold standard for minimal HE diagnosis in research settings [68]
• Battery of 5 paper-and-pencil tests: Number Connection Test-A, Number Connection Test-B, Digit Symbol Test, Serial Dotting Test, Line Tracing Test
• Age- and education-adjusted norms required
• Time-consuming (~20 minutes); requires trained administrator
• Score ≤-4 diagnostic of minimal HE

EncephalApp Stroop Test:

• Smartphone-based application; validated, practical bedside tool [69]
• OffTime > 274.9 seconds or > 5 uncorrected errors suggests minimal HE
• Advantages: Quick (less than 5 minutes), no administrator needed, age/education adjusted
• Limitations: Requires smartphone familiarity

Critical Flicker Frequency (CFF):

• Measures temporal resolution of visual perception [70]
• Threshold less than 39 Hz abnormal
• Portable device, quick, minimal learning effect
• Less widely available than Stroop test

Laboratory Investigations to Identify Precipitants

Systematic laboratory workup for every HE episode to identify treatable precipitants: [4]

Infection Screen:

• Blood cultures (×2 sets)
• Urinalysis and urine culture
• Chest radiograph
• Diagnostic paracentesis (if ascites present): Cell count, differential, culture (inoculate blood culture bottles at bedside), albumin, protein
  • "SBP diagnosis: PMN > 250/mm³ [71]"
  • SBP present in 10-30% of hospitalized cirrhotic patients, often asymptomatic
  • Absence of fever/abdominal pain does not exclude SBP

Gastrointestinal Bleeding:

• Hemoglobin, hematocrit (may be normal acutely)
• Stool for occult blood or visible melena/hematochezia
• Nasogastric aspirate if upper GI bleeding suspected
• Consider urgent endoscopy if hemodynamically unstable or significant bleeding

Renal and Electrolyte Function:

• Serum creatinine, urea (hepatorenal syndrome, acute kidney injury)
• Sodium (hyponatremia common precipitant) [25]
• Potassium (hypokalemia impairs ammonia excretion; hyperkalemia in renal failure)
• Bicarbonate (metabolic alkalosis from hypokalemia or vomiting worsens HE)

Liver Function and Coagulation:

• AST, ALT, ALP, GGT, bilirubin (assess severity, exclude acute hepatocellular injury)
• Albumin, INR (synthetic function, Child-Pugh score)
• Worsening synthetic function suggests decompensation or acute-on-chronic liver failure

Additional Tests:

• Complete blood count (anemia from bleeding, leukocytosis in infection, thrombocytopenia baseline)
• Glucose (hypoglycemia, diabetes)
• Calcium, magnesium (metabolic disturbances)
• Toxicology screen if overdose/intoxication suspected
• Thyroid function if altered mental status unexplained (myxedema coma, thyrotoxicosis)

Grading Liver Disease Severity

Child-Pugh Score: Grades cirrhosis severity (A/B/C) using bilirubin, albumin, INR, ascites, encephalopathy. [72] Presence of HE contributes to score; score helps prognostication.

MELD Score: Uses creatinine, bilirubin, INR to predict 3-month mortality. [73] Does not include HE but higher MELD predicts HE development. Used for liver transplant prioritization.

MELD-Na: Incorporates sodium; better predictor than MELD alone, as hyponatremia predicts HE and mortality. [74]

---

7. Management

Management of hepatic encephalopathy involves three pillars: (1) identifying and treating precipitating factors, (2) reducing ammonia production and absorption, and (3) preventing recurrence in those with prior episodes. [6]

General Principles

Immediate Priorities:

• Airway protection: Grade III-IV encephalopathy carries aspiration risk; consider ICU admission and intubation if unable to protect airway
• Exclude alternative diagnoses: Perform investigations outlined above (CT head if grade III-IV or focal signs, septic screen, metabolic panel)
• Identify precipitant: Systematic search for infection, bleeding, constipation, electrolytes, medications, renal failure
• Supportive care: IV fluids (cautious to avoid hyponatremia), nutrition, pressure area care, fall precautions

Treatment of Precipitants

Treating the underlying precipitant is as important as ammonia-lowering therapy and may be sufficient in mild cases. [4]

Infection:

• Empiric antibiotics if infection suspected (while awaiting cultures):
  • "SBP: 3rd-generation cephalosporin (cefotaxime 2g IV TDS or ceftriaxone 2g IV daily) [71]"
  • "Other infections: Tailor to source (pneumonia, UTI, skin/soft tissue)"
• Albumin for SBP: 1.5 g/kg IV within 6 hours, then 1 g/kg on day 3 reduces renal impairment and mortality [75]

Gastrointestinal Bleeding:

• Resuscitation: Target Hb 70-90 g/L (restrictive strategy superior to liberal) [76]
• Variceal bleeding protocol:
  • Terlipressin or octreotide infusion
  • Prophylactic antibiotics (ceftriaxone 1g daily reduces infection, reinfection, mortality) [77]
  • Urgent endoscopy (within 12 hours) for band ligation or sclerotherapy
• Lactulose/enemas: Clear blood from colon to reduce protein load

Constipation:

• Lactulose: Address below; serves dual purpose of laxative and ammonia reduction
• Enemas: If oral intake not possible

Electrolyte Disturbances:

• Hypokalemia: Correct to > 4.0 mmol/L (impairs conversion of NH3 to NH4+ in renal tubules)
• Hyponatremia: Cautious correction if less than 125 mmol/L (maximum 6-8 mmol/L per 24h to avoid osmotic demyelination syndrome) [78]
• Metabolic alkalosis: Correct underlying cause (often hypokalemia, diuretics)

Medications:

• Stop or reduce precipitants: Benzodiazepines, opioids, antipsychotics, sedating antihistamines
• Diuretics: Hold if dehydration, hypokalemia, or renal impairment present

Renal Impairment/Hepatorenal Syndrome:

• Distinguish pre-renal (dehydration, diuretics) from hepatorenal syndrome (HRS)
• HRS type 1: Aggressive treatment with terlipressin + albumin; consider TIPS, transplant evaluation [79]
• Volume expansion if pre-renal

TIPS:

• TIPS creation/revision increases portosystemic shunting and precipitates HE in 10-50% [21]
• If persistent HE after TIPS, consider shunt reduction/occlusion in selected cases

Ammonia-Lowering Therapy

Lactulose

Lactulose (1,4-galactose-fructose disaccharide) is first-line therapy for overt HE. [6,13]

Mechanisms of Action:

1. Colonic acidification: Bacterial metabolism produces short-chain fatty acids, lowering pH from ~7 to ~5. Acidic pH favors conversion of absorbable NH3 to non-absorbable NH4+ (pKa 9.25), trapping ammonia in colon for fecal excretion. [80]
2. Osmotic laxation: Reduces colonic transit time, decreasing ammonia absorption
3. Bacterial modulation: Inhibits ammonia-producing bacteria (Bacteroides, Clostridium); promotes lactobacilli (non-urease-producing)

Dosing:

• Acute overt HE: 30-45 mL (20-30 g) orally TID-QID initially
• Titration target: 2-3 soft, semi-formed bowel movements per day [6]
  • "Under-treatment: less than 2 stools/day, ineffective ammonia reduction"
  • "Over-treatment: Diarrhea (> 4-5 watery stools/day), dehydration, electrolyte disturbance (hypokalemia, hypernatremia), worsening renal function"
• Unable to take orally: Lactulose enema (300 mL in 700 mL water, retain 30-60 min, repeat TID)
• Long-term prophylaxis: 15-30 mL BD-TID adjusted to maintain soft stools

Evidence:

• Cochrane review: Lactulose improves HE compared to placebo/no intervention (RR 0.62, 95% CI 0.46-0.84) though quality of evidence limited [81]
• Observational data strongly support efficacy; RCT data hampered by difficulty of blinding and placebo control
• Time to improvement: Typically 24-48 hours

Adverse Effects:

• GI: Bloating, cramping, flatulence (very common), diarrhea
• Metabolic: Dehydration, hypokalemia, hypernatremia (from excessive diarrhea)
• Aspiration risk: Vomiting in obtunded patients (use NG tube cautiously)
• Non-compliance: Unpalatable taste, GI side effects

Alternatives to Lactulose:

• Lactitol: Another non-absorbable disaccharide, similar efficacy and side effect profile; not available in all countries [82]

Rifaximin

Rifaximin is a non-absorbable antibiotic that reduces ammonia-producing gut bacteria. [7]

Indications:

• Secondary prevention of recurrent HE: Added to lactulose in patients with ≥2 episodes in 6 months
• Not routinely used as monotherapy for acute HE (lactulose remains first-line)

Dosing:

• 550 mg orally twice daily (BD) continuously

Mechanism:

• Minimally absorbed (less than 0.4% bioavailability); acts locally in gut
• Inhibits bacterial RNA synthesis, reducing urease-producing bacteria (particularly Gram-negative and anaerobes)
• Reduces bacterial ammonia production and potentially gut-derived inflammatory mediators

Evidence:

• Pivotal RCT (Bass et al., NEJM 2010): 299 patients in remission on lactulose randomized to rifaximin 550 mg BD vs. placebo [7]
  • "Breakthrough HE episodes: 22% rifaximin vs. 46% placebo (HR 0.42, pless than 0.001)"
  • "HE-related hospitalization: 14% vs. 23% (HR 0.50, p=0.01)"
  • Maintained benefit over 6 months
  • NNT = 4 to prevent one HE recurrence over 6 months
• Combination lactulose + rifaximin superior to lactulose alone for preventing recurrence [83]

Adverse Effects:

• Generally well tolerated
• GI: Nausea (14%), peripheral edema (15%), fatigue (12%), ascites (11%) - rates similar to placebo
• Concerns about C. difficile risk unfounded (low systemic absorption)
• Antibiotic resistance: Theoretical concern but not demonstrated clinically in long-term studies

Cost Considerations:

• Expensive (~$1500-2000/month in US); cost-effectiveness demonstrated through reduced hospitalizations [84]
• Reserved for recurrent HE rather than first episode in many healthcare systems

L-Ornithine L-Aspartate (LOLA)

LOLA provides substrates for ammonia detoxification pathways. [85]

Mechanism:

• Ornithine stimulates urea cycle (residual hepatic capacity) and carbamoyl phosphate synthetase
• Aspartate provides substrate for glutamine synthesis in muscle
• Enhances skeletal muscle ammonia metabolism

Dosing:

• IV: 20-40 g/day infusion over 4 hours for acute HE
• Oral: 9-18 g/day in divided doses (lower bioavailability)

Evidence:

• Meta-analysis: LOLA reduces ammonia and improves HE in cirrhosis (beneficial effect on mental state, number connection test) [85]
• Primarily studied in Europe and Asia; less commonly used in North America
• May have role as adjunct but not superior to lactulose

Availability:

• Not approved in US/UK; available in Europe, Asia, Australia

Branched-Chain Amino Acids (BCAAs)

BCAAs (leucine, isoleucine, valine) theoretically correct amino acid imbalance. [86]

Mechanism:

• Compete with aromatic amino acids for blood-brain barrier transport
• Reduce false neurotransmitter formation
• Provide alternative nitrogen disposal in muscle

Evidence:

• Meta-analysis shows modest benefit for chronic HE but not acute episodes [86]
• Inferior to lactulose and rifaximin
• High cost, poor palatability

Current role: Not routinely recommended; possible role in patients intolerant of lactulose/rifaximin

Other Agents

Flumazenil:

• GABA-A receptor antagonist
• IV administration; transient improvement in some HE patients [47]
• Not practical for routine use (requires IV access, short duration, expensive)
• May have role in refractory cases or differentiating HE from other causes

Zinc Supplementation:

• Zinc is urea cycle enzyme cofactor; cirrhotic patients often deficient [56]
• Modest benefit in zinc-deficient patients
• Dose: 220 mg zinc sulfate BD
• Consider in patients with documented zinc deficiency

Probiotics:

• Modulation of gut flora to reduce ammonia production
• Mixed evidence; some studies show benefit, others neutral [87]
• Not currently recommended in guidelines but may have adjunctive role

Sodium Benzoate/Phenylacetate:

• Conjugate with glycine/glutamine to form hippurate/phenylacetylglutamine, promoting nitrogen excretion via alternative pathways
• Used primarily in urea cycle defects
• Limited data in HE; second-line agent when standard therapy fails

Nutritional Management

Protein Intake: Historical practice of protein restriction is obsolete and harmful. [16]

• Target: 1.2-1.5 g/kg/day protein (same as for all cirrhotic patients)
• Rationale: Cirrhotic patients are catabolic and sarcopenic; protein restriction worsens malnutrition, sarcopenia, and outcomes
• Evidence: Protein restriction does not reduce HE risk and worsens survival [88]
• Protein source: Vegetable and dairy proteins may be better tolerated than meat (less ammonia production), but restriction not necessary [89]

Energy:

• 35-40 kcal/kg/day to prevent catabolism
• Frequent small meals (4-6/day) + late evening snack to reduce overnight catabolism

Branched-Chain Amino Acid Supplementation:

• Consider in patients who cannot meet protein targets through diet
• Oral BCAA supplements or BCAA-enriched formulas

Micronutrients:

• Zinc supplementation if deficient
• Thiamine (especially in alcoholic liver disease to prevent Wernicke encephalopathy)
• Multivitamin

Management by HE Grade

Grade I-II (Mild-Moderate):

• Oral lactulose 30-45 mL TID-QID, titrate to 2-3 soft stools/day
• Identify and treat precipitant (septic screen, correct electrolytes, stop sedatives)
• Maintain oral nutrition and hydration
• Outpatient management possible if home support adequate, grade I only
• Close monitoring (daily review initially)

Grade III (Severe, Obtunded but Arousable):

• Hospital admission, consider ICU
• Airway assessment: Risk of aspiration; consider intubation if unable to protect airway
• Lactulose via NG tube (if safe) or enemas
• Intensive search for precipitant (CT head, LP if indicated, diagnostic paracentesis, cultures)
• IV fluids, electrolyte correction, empiric antibiotics if infection suspected
• Avoid sedatives (worsens encephalopathy)
• Bladder catheter for monitoring (oliguric AKI common)

Grade IV (Coma):

• ICU admission mandatory
• Intubation for airway protection
• Lactulose via NG tube or enemas (continue despite intubation)
• Neuroimaging (CT head) to exclude structural lesions
• Consider EEG to exclude non-convulsive status epilepticus
• Acute liver failure: Assess for cerebral edema (CT, intracranial pressure monitoring in some centers), mannitol if raised ICP, urgent transplant evaluation [19]
• Cirrhotic HE: Usually reversible with precipitant treatment; if not improving within 48-72h, consider alternative diagnoses

Secondary Prevention (Recurrent HE)

For patients with ≥2 HE episodes within 6 months despite lactulose: [6]

Rifaximin 550 mg BD added to lactulose:

• Reduces recurrence by 58% (NNT=4) [7]
• Continue indefinitely or until transplantation
• Monitor compliance (cost, twice-daily dosing)

Optimize Lactulose Adherence:

• Ensure patient taking adequate dose (2-3 stools/day)
• Address side effects (taste, bloating, diarrhea)
• Patient/caregiver education on titration

Avoid Precipitants:

• Minimize sedatives, opioids
• Prompt treatment of infections
• Avoid dehydration (careful diuretic use)
• Constipation prevention

Liver Transplantation Evaluation:

• Recurrent or persistent HE despite maximal therapy is a relative indication for transplantation
• MELD exception points may be granted in some jurisdictions for refractory HE

TIPS Reduction/Occlusion:

• In selected patients with TIPS-induced persistent HE refractory to medical therapy
• Risks: Recurrence of complications TIPS was placed for (ascites, variceal bleeding)
• Considered only in carefully selected cases

Special Situations

Acute Liver Failure:

• Cerebral edema and intracranial hypertension major concerns (25-80% of grade III-IV) [19]
• ICU management: Head elevation 30°, avoid hypotension, maintain normocapnia, hypertonic saline
• Mannitol (0.5-1 g/kg) if signs of raised ICP
• ICP monitoring in some transplant centers (controversial, risk of hemorrhage)
• Urgent transplant evaluation
• Hypothermia (32-34°C) may reduce ICP in refractory cases

Minimal (Covert) HE:

• Treatment controversial as clinical significance debated
• Consider treatment if impacting quality of life, employment, driving safety
• Lactulose or rifaximin improves psychometric performance [90]
• Driving assessment if impaired (equivalent to alcohol 0.05-0.08%) [33]

Post-TIPS HE:

• Occurs in 10-50% within first year [21]
• Manage with lactulose ± rifaximin
• If persistent and refractory: Consider TIPS reduction (narrower diameter stent) or occlusion (risks recurrence of indication for TIPS)

---

8. Complications

Short-Term Complications

Aspiration Pneumonia:

• Risk in grade II-IV due to altered consciousness and impaired airway reflexes
• Prevention: Nil by mouth if grade III-IV, elevate head of bed, consider NG feeding only if airway protected
• Treatment: Broad-spectrum antibiotics covering anaerobes and Gram-negatives

Falls and Trauma:

• Asterixis, ataxia, confusion increase fall risk
• Subdural hematoma risk increased (coagulopathy, thrombocytopenia)
• Prevention: Supervised ambulation, bed rails, toileting assistance

Pressure Ulcers:

• Prolonged immobility in grade III-IV, malnutrition, hypoalbuminemia
• Prevention: Turning regimen, pressure-relieving mattress, skin care

Cerebral Edema (Acute Liver Failure):

• Occurs in 25-80% of grade III-IV HE in ALF (rare in cirrhotic HE) [19]
• Mechanism: Astrocyte swelling from glutamine accumulation
• Manifestations: Bradycardia, hypertension (Cushing reflex), pupillary changes, decerebrate posturing
• Complications: Brainstem herniation (tonsillar, uncal), irreversible brain injury
• Management: Mannitol, hypertonic saline, hypothermia, urgent transplantation

Seizures:

• Rare (less than 5%) but more common in ALF than cirrhotic HE
• Precipitated by severe hyponatremia, hypoglycemia, alcohol withdrawal
• Treatment: Benzodiazepines cautiously (may worsen encephalopathy), correct metabolic abnormalities

Medium-Term Complications

Hepatorenal Syndrome:

• HE and HRS frequently coexist; HRS type 1 precipitates/worsens HE
• Mortality 80-90% without transplantation
• Treatment: Terlipressin + albumin, TIPS, transplantation [79]

Recurrent Episodes:

• 40% recurrence within 6 months after first episode without prophylaxis [7]
• Each episode increases mortality risk
• Impairs quality of life, employability, caregiver burden

Hospital Readmissions:

• 30-40% readmitted within 30 days [31]
• Driven by recurrent HE, infection, renal impairment, non-adherence to lactulose
• High healthcare costs (~$7.2 billion annually in US) [30]

Long-Term Complications

Persistent Cognitive Impairment:

• Some patients have incomplete recovery after overt HE
• Persistent minimal HE or subtle deficits in executive function, attention, psychomotor speed
• May reflect irreversible neuronal injury or ongoing subclinical HE

Acquired Hepatocerebral Degeneration:

• Rare (less than 1%), irreversible syndrome in patients with long-standing portosystemic shunting
• Progressive cerebellar ataxia, choreoathetosis, dementia, parkinsonian features [62]
• MRI: T1 hyperintensity in basal ganglia (manganese)
• No effective treatment; portosystemic shunt occlusion may halt progression

Hepatic Myelopathy:

• Rare (1-2%), progressive spastic paraparesis from chronic portosystemic shunting [61]
• Irreversible; distinguishing from spinal cord compression critical

Sarcopenia and Frailty:

• Recurrent HE episodes associated with accelerated muscle loss (catabolic stress, reduced mobility, inadequate nutrition)
• Sarcopenia predicts further HE episodes, creating vicious cycle [26]
• Prevention: Maintain protein intake 1.2-1.5 g/kg/day, resistance exercise when able

Reduced Quality of Life:

• Persistent impairment in physical functioning, mental health, social functioning even after HE resolution [32]
• Employment: Unable to work in 40-60% after recurrent HE
• Driving restrictions (minimal HE impairs driving) [33]
• Social isolation, depression, anxiety

Mortality:

• 1-year survival 42% after first episode of overt HE [8]
• Median survival 12 months
• HE is marker of advanced liver disease and predictor of death
• Liver transplantation improves survival (1-year post-transplant survival ~90%)

Impact on Caregivers

Caregiver Burden:

• Substantial psychological, physical, and financial burden on family members [34]
• Responsibilities: Medication administration and monitoring (lactulose titration), preventing precipitants (infection, constipation), recognizing early signs of recurrence
• Caregiver depression and anxiety common
• Reduced caregiver productivity and employment

Interventions:

• Caregiver education on HE recognition and management
• Respite care
• Support groups
• Transplantation (definitive treatment, eliminates ongoing HE risk)

---

9. Prognosis and Outcomes

Survival

Development of overt hepatic encephalopathy is a poor prognostic marker indicating advanced liver disease. [8]

Survival Statistics:

• 1-year survival after first episode of overt HE: 42% (range 35-50% across studies) [8]
• Median survival: 12 months from first overt HE episode
• Survival by HE type:
  • "Type A (acute liver failure): 30-40% survival without transplantation; 60-80% with transplantation [19]"
  • "Type C (cirrhosis): 42% 1-year survival, worse with recurrent episodes"

Factors Predicting Mortality:

• Severity of underlying liver disease (Child-Pugh C, high MELD score)
• Recurrent or persistent HE despite treatment
• Development of HE in context of acute-on-chronic liver failure
• Coexisting complications (hepatorenal syndrome, sepsis, variceal bleeding)
• Older age, malnutrition, sarcopenia [26]

Functional Outcomes

Cognitive Recovery:

• Most patients with episodic HE return to baseline cognitive function after precipitant treatment
• Recovery time: Typically 48-72 hours; may be prolonged (1-2 weeks) in severe episodes
• Incomplete recovery in 10-20%: Residual cognitive deficits, persistent minimal HE

Minimal HE Persistence:

• Prevalent in 30-80% of cirrhotic patients even without overt HE [11]
• Prognostic significance: Predicts development of overt HE (OR 2.5-4.8) and mortality [60]
• Impact on daily functioning: Impaired driving, reduced work capacity, falls risk

Quality of Life:

• Marked impairment across physical, mental, and social domains [32]
• Does not fully normalize even after clinical resolution
• Recurrent HE associated with progressive QoL deterioration

Liver Transplantation

Transplantation Indications:

• Recurrent HE (≥2 episodes within 6 months) despite maximal medical therapy
• Persistent HE unresponsive to treatment
• Overt HE is a relative indication; assessed in context of overall liver disease severity (MELD score, Child-Pugh class, other decompensation events)

Post-Transplant Outcomes:

• HE resolution: > 95% of patients have complete resolution of HE after transplantation [91]
• Cognitive function: Marked improvement, though some subtle deficits may persist (possibly related to immunosuppression, prior cerebral injury)
• Survival: 1-year survival ~90%, 5-year survival ~75-80%
• Quality of life: Substantial improvement in physical and mental health domains

MELD Exception:

• Some jurisdictions grant MELD exception points for refractory HE to increase transplant priority
• Criteria vary but generally require: Recurrent admissions for HE, documentation of non-adherence exclusion, failure of rifaximin + lactulose

Predictive Models

Child-Pugh Score:

• HE grade contributes to score (1-3 points for none/grade I-II/grade III-IV)
• Class C (≥10 points): 1-year survival 45%, 2-year 35% [72]

MELD Score:

• Does not directly include HE but correlates with HE risk
• Higher MELD predicts mortality; used for transplant allocation [73]

Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA):

• Includes encephalopathy as one of six organ systems
• Predicts short-term mortality in acute-on-chronic liver failure [92]

---

10. Examination Focus

Viva Stem: Approach to Hepatic Encephalopathy

"A 58-year-old man with alcohol-related cirrhosis is brought to ED confused. How would you approach this?"

Initial Assessment (ABCDE approach):

• Airway: Grade III-IV encephalopathy - risk of aspiration; assess GCS, consider intubation if less than 8
• Breathing: Respiratory rate, oxygen saturation
• Circulation: Hypotension may indicate sepsis, bleeding; tachycardia
• Disability: GCS, pupillary responses, focal neurology, blood glucose (exclude hypoglycemia immediately)
• Exposure: Signs of chronic liver disease (jaundice, ascites, spider nevi), stigmata of bleeding (melena, hematemesis)

Clinical Grading: Use West Haven Criteria to grade severity (I-IV based on consciousness, cognitive function, asterixis). Asterixis present in grade II (ask patient to extend arms, dorsiflex wrists - flapping tremor). Fetor hepaticus if present (sweet, musty breath).

Differential Diagnosis: Do not assume confusion = HE. Exclude:

• Intracranial pathology: Subdural hematoma (coagulopathy, falls), stroke - CT head if grade III-IV or focal signs
• Infection: Meningitis/encephalitis (fever, neck stiffness) - LP if indicated
• Metabolic: Hypoglycemia (check immediately), hyponatremia, uremia, Wernicke encephalopathy (thiamine deficiency - give IV thiamine)
• Toxic: Alcohol intoxication/withdrawal, medication overdose

Identify Precipitant (present in 80-90%): Systematic search:

1. Infection (25-35%): Septic screen - blood cultures, urine, CXR, diagnostic paracentesis (SBP defined as ascitic PMN > 250/mm³)
2. GI bleeding (15-25%): Check Hb, stool occult blood, melena
3. Constipation (10-15%): Bowel history
4. Electrolytes: U&E (hypokalemia, hyponatremia), renal function (HRS)
5. Medications: Sedatives, opioids, benzodiazepines
6. Dehydration: Overzealous diuretics

Investigations:

• Bedside glucose
• FBC (anemia, infection), U&E (electrolytes, creatinine), LFTs (synthetic function - albumin, INR)
• Ammonia: Supportive but not diagnostic; poor correlation with severity; do not use to monitor treatment
• Blood cultures, urinalysis, CXR
• Diagnostic paracentesis (if ascites): Cell count, culture, albumin
• CT head: If grade III-IV, focal signs, concern for ICH/stroke
• EEG: If atypical features; shows triphasic waves (non-specific), generalized slowing

Management:

Acute Treatment:

1. Treat precipitant:

   • Infection: Empiric antibiotics (cefotaxime 2g TDS for SBP) + albumin 1.5 g/kg then 1 g/kg day 3
   • Bleeding: Resuscitation, terlipressin/octreotide, endoscopy
   • Electrolytes: Correct K+, Na+
   • Stop sedatives

2. Lactulose:

   • 30-45 mL TID-QID orally, titrate to 2-3 soft stools/day
   • Works by acidifying colon (NH3 → NH4+), laxative effect reducing transit time
   • Enemas if unable to take PO
   • NOT for monitoring: Ammonia trends do not guide therapy

3. Supportive:

   • Airway protection if grade III-IV
   • IV fluids, nutrition (do NOT restrict protein - maintain 1.2-1.5 g/kg/day)
   • Avoid sedatives

Secondary Prevention (recurrent HE ≥2 episodes in 6 months):

• Rifaximin 550 mg BD + lactulose
• Bass NEJM 2010 trial: 58% reduction in recurrence (NNT=4) [7]
• Non-absorbable antibiotic reducing ammonia-producing gut bacteria

Prognosis:

• 1-year survival 42% after first overt HE episode [8]
• Median survival 12 months
• Indication for transplant evaluation

Key Viva Points:

1. HE is clinical diagnosis - ammonia supportive only, do not over-rely
2. Always search for precipitant (infection most common) - treating precipitant as important as lactulose
3. Do NOT restrict protein (outdated, harmful)
4. Rifaximin for secondary prevention, not acute treatment
5. Development of HE = poor prognosis, consider transplant

---

West Haven Criteria Deep Dive

Examiners frequently ask candidates to grade HE severity and describe features:

Asterixis Technique (commonly asked to demonstrate):

• "Ask patient to extend arms in front, dorsiflex wrists (like stopping traffic)"
• "Irregular, non-rhythmic flapping motion - brief loss of extensor tone"
• "Bilateral but may be asymmetric"
• "Also test at ankles if obtunded (dorsiflex foot)"
• "Absent in deep coma (grade IV)"

---

Ammonia Metabolism for Exam

"Describe ammonia metabolism and why it accumulates in HE"

Normal Physiology:

• "Ammonia (NH3) produced in colon from bacterial degradation of proteins and urea, and in small intestine from glutamine metabolism"
• "Portal blood delivers ammonia to liver where it's detoxified via two pathways:"
  1. "Urea cycle (periportal hepatocytes): NH3 → urea, excreted in urine"
  2. "Glutamine synthesis (perivenous hepatocytes): NH3 + glutamate → glutamine"
• "Normal first-pass hepatic extraction 80-90%, maintaining low systemic ammonia"

HE Pathophysiology:

• "Two mechanisms cause hyperammonemia in cirrhosis:"
  1. "Impaired hepatocellular function - reduced functional hepatocyte mass, decreased urea cycle activity"
  2. "Portosystemic shunting - portal-systemic collaterals bypass liver, allowing ammonia direct access to systemic circulation"
• "Skeletal muscle becomes alternative detox site (glutamine synthesis), explaining why sarcopenia worsens HE"

Cerebral Toxicity:

• "Ammonia crosses blood-brain barrier as lipophilic NH3"
• "Astrocytes convert NH3 to glutamine (via glutamine synthetase)"
• "Glutamine accumulation → osmotic stress → astrocyte swelling (Alzheimer type II astrocytosis)"
• "Mitochondrial dysfunction, oxidative stress, energy depletion"
• "In acute liver failure: Cytotoxic cerebral edema, raised ICP, herniation risk"

"Why don't we use ammonia levels to diagnose or monitor HE?"

• "Poor correlation with severity (sensitivity 47-85%, specificity 31-76%)" [65]
• "False negatives: 10% with clinical HE have normal ammonia"
• "False positives: Elevated in GI bleeding, high protein meal, hemolysis, muscle activity without HE"
• "Trends don't track clinical improvement reliably"
• "HE is clinical diagnosis; ammonia may support but not confirm or exclude"

---

Lactulose vs. Rifaximin: Evidence

Lactulose:

• "First-line for acute overt HE"
• "Mechanisms: (1) Colonic acidification - converts NH3 to NH4+ (non-absorbable), (2) Osmotic laxative - reduces transit time"
• "Dose: 30-45 mL TID-QID, titrate to 2-3 soft stools/day - critical point"
• "Evidence: Cochrane review shows benefit vs. placebo (RR 0.62) though quality of evidence limited" [81]
• "Adverse effects: Bloating, diarrhea; over-treatment → dehydration, hypokalemia, worsens renal function"

Rifaximin:

• "Non-absorbable antibiotic, reduces ammonia-producing gut bacteria"
• "Indication: Secondary prevention of recurrent HE (≥2 episodes), added to lactulose, NOT monotherapy for acute HE"
• "Dose: 550 mg BD continuously"
• "Evidence: Bass NEJM 2010 RCT - rifaximin + lactulose vs. placebo + lactulose:" [7]
  • "Breakthrough HE: 22% vs. 46% (HR 0.42, pless than 0.001)"
  • "HE-related hospitalization: 14% vs. 23% (HR 0.50)"
  • "NNT = 4 to prevent one recurrence over 6 months"
• "Well tolerated, minimal side effects"
• "Cost: Expensive (~$1500-2000/month US), cost-effective through reduced admissions"

Common Exam Error: Saying rifaximin for acute HE - it's for prevention, not acute treatment.

---

High-Yield Exam Facts

1. Most common precipitant: Infection (25-35%), especially SBP [4]
2. Diagnostic paracentesis: Mandatory if ascites present - SBP often asymptomatic, defined as PMN > 250/mm³ [71]
3. Protein restriction: OBSOLETE - maintain 1.2-1.5 g/kg/day, restriction worsens outcomes [16]
4. Lactulose target: 2-3 soft stools/day (not diarrhea, not constipation) [6]
5. Ammonia: Do NOT use to diagnose, grade, or monitor [14]
6. Triphasic waves on EEG: Suggestive but NON-SPECIFIC (also uremia, hyponatremia) [67]
7. 1-year survival: 42% after first overt HE episode [8]
8. Rifaximin: Secondary prevention only, not acute treatment [7]
9. Cerebral edema: Common in ALF (25-80%), rare in cirrhotic HE [19]
10. Transplant: Recurrent/persistent HE despite maximal therapy is indication for evaluation

---

11. References

1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735. PMID: 25042402

2. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002;17(4):221-227. PMID: 12602499

3. Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79(Suppl 1):5-9. PMID: 30706420

4. Mumtaz K, Ahmed US, Abid S, et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Physicians Surg Pak. 2010;20(8):514-518. PMID: 20688016

5. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72(4 Pt 1):573-583. PMID: 14049

6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-824. PMID: 35724931

7. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081. PMID: 20335583

8. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895. PMID: 10365817

9. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-721. PMID: 11870389

10. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9. PMID: 17295846

11. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739-747. PMID: 21306407

12. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114(3):188-193. PMID: 12637132

13. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046. PMID: 15054035

14. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem. 2005;38(8):696-699. PMID: 15963972

15. Nicolao F, Efrati C, Masini A, et al. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol. 2003;38(4):441-446. PMID: 12663235

16. Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43. PMID: 15246205

17. Romero-Gómez M, Boza F, García-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718-2723. PMID: 11569700

18. Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675-1682. PMID: 20186843

19. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534. PMID: 24369077

20. Lee WM, Larson AM, Stravitz RT. AASLD Position Paper: The Management of Acute Liver Failure: Update 2011. Hepatology. 2011. Available at: www.aasld.org

21. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103(11):2738-2746. PMID: 18775022

22. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126(2):469-475. PMID: 14762784

23. Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35(1):37-45. PMID: 11495040

24. Bajaj JS, Pinkerton SD, Sanyal AJ, et al. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology. 2012;55(4):1164-1171. PMID: 22031326

25. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104(6):1382-1389. PMID: 19455124

26. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166-173. PMID: 21893129

27. Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2011;9(2):181-183. PMID: 20951829

28. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979-985. PMID: 20621200

29. Stepanova M, Mishra A, Venkatesan C, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034-1041. PMID: 22642955

30. Poodad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9. PMID: 17295846

31. Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64(1):200-208. PMID: 26690389

32. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45-49. PMID: 9657095

33. Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135(5):1591-1600. PMID: 18723018

34. Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646-1653. PMID: 21556040

35. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol. 2002;67(4):259-279. PMID: 12207972

36. Olde Damink SW, Jalan R, Redhead DN, et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology. 2002;36(5):1163-1171. PMID: 12395327

37. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57(8):1156-1165. PMID: 18628384

38. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999;29(3):648-653. PMID: 10051464

39. Huizenga JR, Gips CH, Tangerman A. The contribution of various organs to ammonia formation: a quantitative study in healthy controls and patients with cirrhosis using a [13N]ammonia infusion technique. Neth J Med. 1996;49(3):135-142. PMID: 8875500

40. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest. 1979;63(3):449-460. PMID: 429564

41. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis. 1996;16(3):245-253. PMID: 8989810

42. Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Hepatology. 1996;24(4):919-923. PMID: 8855198

43. Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis. 2005;20(4):303-318. PMID: 16382341

44. Kosenko E, Kaminsky Y, Grau E, et al. Brain ATP depletion induced by acute ammonia intoxication in rats is mediated by activation of the NMDA receptor and Na+,K+-ATPase. J Neurochem. 1994;63(6):2172-2178. PMID: 7964738

45. Nguyen JH, Yamamoto S, Steers J, et al. Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. J Hepatol. 2006;44(6):1105-1114. PMID: 16458990

46. Ahboucha S, Butterworth RF. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int. 2008;52(4-5):575-587. PMID: 17996988

47. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 1998;28(2):374-378. PMID: 9695999

48. Monfort P, Muñoz MD, Kosenko E, et al. Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J Neurosci. 2004;24(49):10687-10693. PMID: 15564585

49. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet. 1971;2(7715):75-80. PMID: 4103978

50. Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40(2):247-254. PMID: 14739095

51. Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54(4):640-649. PMID: 21146512

52. Butterworth RF. Neuroinflammation in hepatic encephalopathy: mechanistic aspects and therapeutic options. Metab Brain Dis. 2016;31(6):1277-1286. PMID: 27418066

53. Chastre A, Bélanger M, Nguyen BN, et al. Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure. Liver Int. 2014;34(3):353-361. PMID: 24256542

54. Klos KJ, Ahlskog JE, Josephs KA, et al. Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol. 2005;62(9):1385-1390. PMID: 16157745

55. Zieve L. Pathogenesis of hepatic encephalopathy. Metab Brain Dis. 1987;2(3):147-165. PMID: 3306480

56. Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996;23(5):1084-1092. PMID: 8621137

57. Chen S, Zieve L, Mahadevan V. Mercaptans and dimethyl sulfide in the breath of patients with cirrhosis of the liver. Effect of feeding methionine. J Lab Clin Med. 1970;75(4):628-635. PMID: 5443578

58. Schomerus H, Hamster W, Blunck H, et al. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci. 1981;26(7):622-630. PMID: 7249898

59. Montagnese S, Middleton B, Skene DJ, et al. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int. 2009;29(9):1372-1382. PMID: 19422481

60. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95(8):2029-2034. PMID: 10950057

61. Weissenborn K, Tietge UJ, Bokemeyer M, et al. Liver transplantation for hepatic encephalopathy. Intern Med. 2000;39(8):632-636. PMID: 10939533

62. Victor M, Adams RD, Cole M. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration. Medicine (Baltimore). 1965;44(5):345-396. PMID: 5318075

63. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline. Hepatology. 2014;60(2):715-735. PMID: 25042402

64. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455. PMID: 17434099

65. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem. 2005;38(8):696-699. PMID: 15963972

66. Parsons-Smith BG, Summerskill WH, Dawson AM, et al. The electroencephalograph in liver disease. Lancet. 1957;273(7001):867-871. PMID: 13482229

67. Kaplan PW, Sutter R. Affair with triphasic waves - their striking presence, mysterious significance, and cryptic origins: what are they? J Clin Neurophysiol. 2015;32(5):401-405. PMID: 26457753

68. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34(5):768-773. PMID: 11434627

69. Bajaj JS, Thacker LR, Heuman DM, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58(3):1122-1132. PMID: 23389962

70. Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45(4):879-885. PMID: 17393525

71. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417. PMID: 20633946

72. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. PMID: 4541913

73. Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. PMID: 17326206

74. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026. PMID: 18768945

75. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. PMID: 10432325

76. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21. PMID: 23281973

77. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049-1056. PMID: 17030175

78. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589. PMID: 10824078

79. Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576-584. PMID: 19885875

80. Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13(2):177-191. PMID: 6771130

81. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046. PMID: 15054035

82. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology. 1992;15(2):222-228. PMID: 1531595

83. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458-1463. PMID: 23877348

84. Neff GW, Jones M, Broda T, et al. Durability of rifaximin efficacy in treatment of hepatic encephalopathy. Dig Dis Sci. 2012;57(4):1054-1060. PMID: 22147245

85. Soárez PC, Oliveira AC, Padovan J, et al. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment. Arq Gastroenterol. 2009;46(3):241-247. PMID: 19918694

86. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015;2015(9):CD001939. PMID: 26368788

87. Dalal R, McGee RG, Riordan SM, et al. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2(2):CD008716. PMID: 28244109

88. Plauth M, Cabré E, Riggio O, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr. 2006;25(2):285-294. PMID: 16707194

89. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med. 1993;233(5):385-392. PMID: 8478479

90. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45(3):549-559. PMID: 17326150

91. Sotil EU, Gottstein J, Ayala E, et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl. 2009;15(2):184-192. PMID: 19177446

92. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437. PMID: 23474284

---

Last Reviewed: 2026-01-05 | MedVellum Editorial Team